Apremilast/Apremilast

Apremilast is an orally used small-molecule inhibitor of phosphodiesterase-4. It has been approved for the treatment of adult patients with psoriatic arthritis and moderate to severe plaque psoriasis. Clinical studies have reported that it is also effective in hairy skin and nail psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis. In psoriasis vulgaris, a PASI75 response was achieved in 30-70% of the patients in 12-16 weeks. It is generally well-tolerated, and its most common side effects are diarrhea, headache, and nausea, all of which disappear in time. Keywords: Psoriasis, phosphodiesterase inhibitor, apremilast Apremilast, oral olarak kullanilan, kucuk molekullu fosfodiesteraz-4 inhibitorudur. Psoriatik artritli ve orta/jiddetli plak psoriasisli yetijkin hastalarin tedavisinde onaylidir. Yapilan klinik calijmalarda sacli deri, tirnak psoriasisi, jeneralize pustuler psoriasis ve palmoplantar pustulosiste de etkili oldugu bildirilmijtir. Psoriasis vulgariste PAJI75 cevabi hastalarin %30-70'inde 12-16 haftada alinmijtir. Genel olarak iyi tolere edilir, diyare, ba; agrisi ve bulanti en sik gorulen yan etkiler olup zamanla geriler. Anahtar Kelimeler: Psoriasis, fosfodiesteraz inhibitoru, apremilast